System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print 1 citation

PubMed: 42379345 DOI: 10.1016/j.ejvs.2026.06.048

A Randomised Trial of Paclitaxel Coated Balloons in Arteriovenous Fistula Stenosis with Blinded Re-intervention Criteria.

Eur J Vasc Endovasc Surg

Authors: Raphaël Coscas, Lamiae Grimaldi, Lucie Mercier, Éric Picard, Angel Ferrario, Joseph Touma, Alexandros Mallios, Marc Sznajder, Lionelle Nkam, Ziad A Massy

Affiliations

  • Department of Vascular Surgery, Ambroise Paré University Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France; Department of Vascular Surgery, American Hospital of Paris, Neuilly-sur-Seine, France; UMR 1018, Inserm-Paris11 - CESP, Versailles Saint-Quentin-en-Yvelines University, Paris-Saclay University, Paul Brousse Hospital, Villejuif, France.
  • Unité de Recherche Clinique, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France; Faculté de Médecine Simone Veil, Université Versailles Saint Quentin-Université Paris-Saclay, INSERM, CESP Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-Le-Bretonneux, France.
  • Department of Vascular Surgery, Ambroise Paré University Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France; UMR 1018, Inserm-Paris11 - CESP, Versailles Saint-Quentin-en-Yvelines University, Paris-Saclay University, Paul Brousse Hospital, Villejuif, France.
  • Department of Vascular and Thoracic Surgery, Carémeau University Hospital, Nîmes, France.
  • Department of Radiology, Clinique les Fontaines, Melun, France.
  • Department of Vascular Surgery, Henri Mondor University Hospital, Créteil, France; Université Paris-Est Créteil, Créteil, France.
  • Department of Vascular Surgery, Groupe Hospitalier Paris Saint Joseph, Paris, France; Department of Surgery, Centre Hospitalier de Chartres, Le Coudray, France.
  • Unité de Recherche Clinique, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France.
  • UMR 1018, Inserm-Paris11 - CESP, Versailles Saint-Quentin-en-Yvelines University, Paris-Saclay University, Paul Brousse Hospital, Villejuif, France; Department of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt, Paris, France.

Abstract

OBJECTIVE

The aim of this French physician initiated, multicentre, prospective, randomised trial with blinded criteria for re-intervention was to evaluate the efficacy of paclitaxel coated balloons (DCBs) in the treatment of arteriovenous fistula stenosis.

METHODS

One hundred and fifty patients with an arteriovenous fistula stenosis were included, and 145 were randomised 1:1 in the ABISS trial (Angioplastie au Ballon Imprégné de paclitaxel vs. angioplastie Standard pour le traitement des Sténoses sur fistule artérioveineuse; ClinicalTrials.gov identifier: NCT02753998) between a DCB (Lutonix, BD, Franklin Lakes, NJ, USA) and a placebo balloon. The main outcome was the rate of primary patency loss at 6 months. The primary analysis was performed in the modified intention to treat population. Missing outcome data were handled using a conservative imputation approach. The per-protocol analysis excluded patients who were included by mistake, not treated according to the randomisation arm, lost to follow up, or who missed a visit.

RESULTS

In the modified intention to treat analysis, there was no significant difference between the groups regarding primary patency loss at 6 months (31% [22 of 70] in the DCB group vs. 42% [30 of 71] in the placebo group; p = .09; hazard ratio = 0.62 [95% confidence interval {CI} 0.36 - 1.07]). Primary patency loss was lower in the DCB than in the placebo group at 3 months (4.2% vs. 22.5%; p = .002; hazard ratio = 0.18 [95% CI 0.05 - 0.60]), but not at 12 months (58.6% vs. 57.7%; p = .57; hazard ratio = 0.88 [95% CI 0.57 - 1.35]). In the per-protocol analysis, the primary patency loss was significantly lower in the DCB group than in the placebo group (26% [16 of 61] in the DCB group vs. 50% [28 of 56] in the placebo group; p = .004).

CONCLUSION

In the ABISS trial, the use of a DCB was not superior to a placebo balloon at 6 months in the modified intention to treat analysis.

MeSH

Constriction, Pathologic, Fistula, Intention To Treat Analysis, Paclitaxel, Arteriovenous Fistula